PHAXIAM Therapeutics (XPAR:PHXM) Short Interest


XPAR:PHXM PHAXIAM Therapeutics SA XPAR:PHXM
38 GF Score
Price €0.10
View Full Analysis

What is PHAXIAM Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XPAR:PHXM vs VRTX, REGN, SGEN: Short Interest Comparison

For the Biotechnology subindustry, PHAXIAM Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PHAXIAM Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's Short Interest falls into.


XPAR:PHXM
38GF Score
PHAXIAM Therapeutics SA XPAR:PHXM
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for XPAR:PHXM

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price